// App-Quantinova.ai

S136 : A PHASE IB/II STUDY OF IVOSIDENIB WITH VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED MYELOID MALIGNANCIES

Researchers

Presenter

  • Curtis Lachowiez

Principal Investigators

  • Sanam Loghavi

  • Zhihong Zeng

  • Tapan Kadia

  • Lucia Masarova

  • Koichi Takahashi

  • George Tippett

  • Samantha Smith

  • Jacqueline Garcia

  • Prithviraj Bose

  • Elias Jabbour

  • Farhad Ravandi

  • Naval Daver

  • Guillermo Garcia-Manero

  • Bilyana Stoilova

  • Paresh Vyas

  • Hagop Kantarjian

  • Marina Konopleva

  • Courtney DiNardo

Medical Centers

  • Department of Hematopathology,The University of Texas M.D. Anderson Cancer Center,Houston,United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Department of Hematology,OUH NHS Trust,Oxford,United Kingdom

  • Department of Leukemia,University of Texas MD Anderson Cancer Center,Houston,Vereinigte Staaten

  • Leukemia Program,Dana-Farber Cancer Institute,Boston,United States

  • NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved